Pentosan Polysulfate Maculopathy Following Subcutaneous Injections for Arthritis
The findings of this case series suggest that PPS retinal toxic effects can occur with subcutaneous administration alone, at much lower doses than typically occurs with oral administration, potentially due to 10-fold higher bioavailability. Early recognition of this toxic maculopathy with multimodal imaging is important to limit exposure to this drug and avoid incorrect treatments. Given progression of maculopathy even following cessation, caution is advised when using subcutaneous PPS.
Authors
- Alessandro Feo (ORCID: https://orcid.org/0009-0005-2999-6782)
- Alex P. Hunyor (ORCID: https://orcid.org/0000-0002-8182-6167)
- David Sarraf (ORCID: https://orcid.org/0000-0003-4018-2702)
- Shahin Faghihi (ORCID: https://orcid.org/0000-0003-1314-2676)
- Nicolas A. Yannuzzi (ORCID: https://orcid.org/0009-0004-0035-7373)
- L. Lim
- José M. Carrillo
- Adrian T. Fung (ORCID: https://orcid.org/0000-0002-1117-3893)
- Consuelo Borie (ORCID: https://orcid.org/0000-0001-9123-9444)
Institutions
- The University of Sydney (AU)
- Humanitas University (IT)
- University of Miami (US)
- Sun Yat-sen University (CN)
- Westmead Hospital (AU)
- Coffs Harbour City Council (AU)
- Doheny Eye Institute (US)
- Hospital de Especialidades (MX)
- VA Greater Los Angeles Healthcare System (US)
- Macquarie University (AU)
Publication Details
- Journal
- JAMA Ophthalmology
- Published
- 2025-12-11
- DOI
- https://doi.org/10.1001/jamaophthalmol.2025.5069
- Citations
- 1
- Primary Topic
- Ocular Infections and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 1.71